[Therapy-resistant cutaneous infiltrates in chronic lymphocytic leukemia].
Chronic lymphocytic leukemia (CLL) is a low-grade B-cell non-Hodgkin lymphoma. Skin involvement is observed in up to 25% of patients. A 70-year-old men with presented with prominent erythematous facial infiltrates. After the diagnosis of CLL was established, he showed a good hematologic response to the monoclonal antibody rituximab, but the skin infiltrates were therapy-resistant.
Sucker
C
C
Klinik und Poliklinik für Innere Medizin C, Ernst-Moritz-Arndt Universität Greifswald, Germany.
Lorenz
G
G
Dölken
G
G
Stockschläder
M
M
D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004351:Drug Resistance; D005145:Face / Q000473:pathology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D017254:Leukemic Infiltration / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000069283:Rituximab; D012867:Skin / Q000473:pathology*; D013997:Time Factors
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D000069283:Rituximab